NCT06258668View on ClinicalTrials.gov

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

RecruitingOBSERVATIONAL
Enrollment

505

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Moderate-to-severe Plaque Psoriasis
Interventions
DRUG

Deucravacitinib

As per product label

Trial Locations (2)

06234

WITHDRAWN

Local Institution - 0001, Seoul

RECRUITING

Novotech Laboratory Korea Co., Ltd., Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06258668 - Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea | Biotech Hunter | Biotech Hunter